公开(公告)号：WO2023079153A1

公开(公告)日：2023-05-11

申请号：PCT/EP2022/081018

申请日：2022-11-07

申请人： HOOKIPA BIOTECH GMBH

发明人： LAUTERBACH, Henning ,  LAMPERT, Jörg Christoph ,  HABBEDDINE, Mohamed ,  RAGUZ, Josipa ,  SCHIPPERS, Timo ,  SCHMIDT, Sarah ,  AHMADI-ERBER, Sarah ,  ROSSKOPF, Sandra ,  ORLINGER, Klaus ,  MATUSHANSKY, Igor

IPC分类号： A61K39/00 ,  C07K14/00 ,  C12N7/00

摘要： The invention relates to genetically modified arenaviruses suitable for the treatment of neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus, wherein the arenavirus has been engineered to include a nucleotide sequence encoding one or more antigenic fragment(s) of mutant KRAS alone or to further include a nucleotide sequence encoding one or more antigenic fragment(s) of a mutated cancer driver gene (e.g., a mutant TP53) or a tumor-associated antigen.

公开(公告)号：WO2023076820A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/078297

申请日：2022-10-18

申请人： NAVICURE BIOPHARMACEUTICALS LIMITED ,  SAUNDERS, Paul

发明人： WU, Chia-Mao

IPC分类号： A61K39/12 ,  C07K14/005 ,  A61P31/12 ,  C07K16/10 ,  C12N7/00

摘要： Immunogenic fusion proteins against coronavirus. A fusion protein is disclosed, which comprises a CD40-binding domain; an antigen of SARS-CoV2; a translocation domain located between the CD40-binding domain and the antigen, and a furin and/or cathepsin L cleavage site located between the CD40-binding domain and the translocation domain. In one embodiment, the translocation domain is a Shiga toxin (Stx) translocation peptide, and the antigen is located at the N-terminal of the fusion protein. In another embodiment, the translocation domain is a Pseudomonas Exotoxin A (PE) translocation peptide, and the CD40-binding domain is located at the N-terminal of the fusion protein. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, and/or for reducing, inhibiting, treating and/or ameliorating symptoms caused by SARS-CoV2 infection in a subject in need thereof.

公开(公告)号：WO2023069998A1

公开(公告)日：2023-04-27

申请号：PCT/US2022/078377

申请日：2022-10-19

申请人： AMGEN INC.

发明人： KAHL, Christoph Adrian ,  KIM, Haejin

IPC分类号： C12N15/867 ,  C07K14/155 ,  C12N7/00 ,  C12N7/02

摘要： Disclosed herein are lentiviral plasmid packaging compositions comprising unique mass ratios of four plasmids that are useful in producing lentiviral vectors. Also provided are methods of producing such lentiviral vectors by mixing a complexation solution comprising the lentiviral plasmid packaging composition with a transfection reagent and incubating the mixture for at least 10 minutes, transfecting a eukaryotic host cell with the lentiviral plasmid packaging composition, adding sodium butyrate to the transfected host cells about one day after transfection, and culturing the host cell. Exemplary embodiments of the method comprise a concentration of total plasmid in pg/mL of 0.25-3 and/or a mass ratio of total plasmid mass in pg to the mass of transfection reagent in pg extending from about 1:1 to about 1:3.

公开(公告)号：WO2023063769A1

公开(公告)日：2023-04-20

申请号：PCT/KR2022/015581

申请日：2022-10-14

申请人： (주)지노믹트리

发明人： 안성환

IPC分类号： C12N15/63 ,  C12N7/00 ,  A61K48/00

摘要： 본 발명은 mRNA 발현을 위한 유전자 구조체, 상기 유전자 구조체를 포함하는 약제학적 조성물, 백신 조성물 및 유전자 치료용 조성물에 관한 것으로, 더욱 상세하게는 코로나바이러스 (SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2) 유래 5' 비번역 영역 (UTR) 및/또는 3' 비번역 영역 (UTR)을 포함하는 유전자 구조체, 상기 유전자 구조체를 포함하는 약제학적 조성물, 백신 조성물 및 유전자 치료용 조성물에 관한 것이다.

公开(公告)号：WO2023063453A1

公开(公告)日：2023-04-20

申请号：PCT/KR2021/014331

申请日：2021-10-15

申请人： 주식회사 마이크로바이오틱스

发明人： 한창구 ,  김경남 ,  서현수

IPC分类号： C12N7/00 ,  A01N63/40 ,  A61K35/76 ,  A61P31/00 ,  A23L33/135 ,  A23K10/16 ,  A23K20/195

摘要： 본 발명은 항생제에 내성을 나타내는 슈도모나스 균속을 용균시키는 박테리오파지에 관한 것이다. 구체적으로, 상기 슈도모나스 균속은 녹농균 (Pseudomonas aeruginosa)에 관한 것일 수 있다.

公开(公告)号：WO2023062328A1

公开(公告)日：2023-04-20

申请号：PCT/FR2022/051939

申请日：2022-10-14

申请人： LESAFFRE ET COMPAGNIE

发明人： BOYER, Mickaël ,  ISRAEL, Alan ,  POULAIN, Edith ,  SOUICI, Jean-Bernard ,  TOUSSAINT, Renaud

IPC分类号： C12N1/04 ,  C12N1/16 ,  C12N7/00 ,  A23L29/00 ,  A21D8/04 ,  A61K35/66 ,  C12G1/00 ,  A21D10/00 ,  A61K35/76 ,  C12R1/865

摘要： La présente demande concerne un procédé de fabrication d'un mélange sec d'au moins une levure et/ou d'un dérivé de levure et d'au moins un bactériophage, ledit mélange se présentant sous forme d'entités solides, chaque entité solide consistant en au moins une levure et/ou au moins un dérivé de levure et au moins un bactériophage et éventuellement au moins un excipient de séchage, ledit procédé étant caractérisé en ce qu'il est effectué par le mélange d'au moins une levure et/ou d'un dérivé de levure et d'au moins un bactériophage en suspension et le séchage de ce mélange. Elle concerne également un mélange sec d'au moins une levure et/ou d'un dérivé de levure et d'au moins un bactériophage, caractérisé en ce qu'il se présente sous forme d'entités solides, chaque entité solide consistant en au moins une levure et/ou au moins un dérivé de levure et au moins un bactériophage et éventuellement au moins un excipient de séchage et ses utilisations.

公开(公告)号：WO2023056521A1

公开(公告)日：2023-04-13

申请号：PCT/AU2022/051202

申请日：2022-10-07

申请人： SEQIRUS PTY LTD

发明人： ROCKMAN, Steven ,  VANDENBERG, Kirsten ,  ONG, Chi

IPC分类号： C12N7/00 ,  G01N33/569 ,  A61K39/00 ,  A61K39/42 ,  A61P31/12 ,  C07K16/10

摘要： The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof.

公开(公告)号：WO2023039638A1

公开(公告)日：2023-03-23

申请号：PCT/AU2022/051120

申请日：2022-09-16

申请人： THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

发明人： KHANA, Rajiv ,  DASARI, Vijayendra

IPC分类号： A61K39/00 ,  A61K39/245 ,  A61P31/22 ,  C12N7/00

摘要： The present invention discloses a novel recombinant polypeptide, and methods for stimulating protective or therapeutic immune responses to human herpesvirus. The invention relates to a composition comprising isolated homotrimers of a modified gB polypeptide from human cytomegalovirus (hCMV), wherein the gB polypeptide comprises an immunoglobulin signal peptide, an extracellular domain with furin cleavage site mutations, and/or the intravirion domain, but lacks the transmembrane domain. Also the use thereof and methods of treating and preventing CMV associated disease or CMV infections with said composition.

公开(公告)号：WO2023034785A1

公开(公告)日：2023-03-09

申请号：PCT/US2022/075647

申请日：2022-08-30

申请人： VIR BIOTECHNOLOGY, INC. ,  LEDOUX, Sarah

发明人： BRUENING, Eric ,  DOUGLAS, Janet L. ,  MEYER, Christine R.

IPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00

摘要： The present disclosure provides methods for producing cytomegalovirus (CMV) viral vectors. The present disclosure also provides methods for modifying host cells for use in producing CMV viral vectors.

公开(公告)号：WO2023026170A1

公开(公告)日：2023-03-02

申请号：PCT/IB2022/057859

申请日：2022-08-23

申请人： VICTORIA LINK LIMITED

发明人： COMOLETTI, Davide ,  CONNOR, Lisa

IPC分类号： A61K39/00 ,  A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  C07K14/165 ,  C12N7/00

摘要： Disclosed herein are fusion polypeptides comprising at least one peptide domain from a severe acute respiratory syndrome coronavirus (SARS CoV-2) spike protein (S-protein), polynucleotides encoding such fusion polypeptides, methods of making such polypeptides and polynucleotides, pharmaceutical compositions and vaccines comprising such polypeptides or polynucleotides, and methods of using such polypeptides and/or polynucleotides for the treatment or prevention of SARS CoV-2 infection in a subject.